Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Finished Goods: 2017-2024

Historic Finished Goods for Adma Biologics (ADMA) over the last 7 years, with Dec 2024 value amounting to $48.1 million.

  • Adma Biologics' Finished Goods rose 2.02% to $64.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.3 million, marking a year-over-year increase of 2.02%. This contributed to the annual value of $48.1 million for FY2024, which is 31.54% down from last year.
  • Latest data reveals that Adma Biologics reported Finished Goods of $48.1 million as of FY2024, which was down 31.54% from $70.3 million recorded in FY2023.
  • Over the past 5 years, Adma Biologics' Finished Goods peaked at $70.3 million during FY2023, and registered a low of $19.2 million during FY2020.
  • In the last 3 years, Adma Biologics' Finished Goods had a median value of $58.5 million in 2022 and averaged $59.0 million.
  • As far as peak fluctuations go, Adma Biologics' Finished Goods spiked by 101.60% in 2022, and later plummeted by 31.54% in 2024.
  • Adma Biologics' Finished Goods (Yearly) stood at $19.2 million in 2020, then spiked by 51.06% to $29.0 million in 2021, then surged by 101.60% to $58.5 million in 2022, then increased by 20.22% to $70.3 million in 2023, then plummeted by 31.54% to $48.1 million in 2024.